PAPER Wyman-Chick KA, Barrett MJ, Miller MJ, Sargent L, Chrenka EA, Kane JP, Crowley SJ, Kuntz JL, Parashos SA, Schousboe JT, Nguyen H, Werner AM, Rossom RC

The relationship between anticholinergic burden and frailty in the year preceding a diagnosis of dementia with Lewy bodies.

Alzheimers Dement (Amst). 2024;16(4):e70034. Epub 2024 Dec 14 PubMed.

PAPER Cohen JS, Phillips J, Das SR, Olm CA, Radhakrishnan H, Rhodes E, Cousins KA, Xie SX, Nasrallah IM, Yushkevich PA, Wolk DA, Lee EB, Weintraub D, Irwin DJ, McMillan CT

Posterior hippocampal sparing in Lewy body disorders with Alzheimer's copathology: An in vivo MRI study.

Neuroimage Clin. 2024 Dec 7;45:103714. Epub 2024 Dec 7 PubMed.

PAPER Travaglia A, Lal S, Pullagura SR

Advancing ALS research: public-private partnerships to accelerate drug and biomarker development.

Trends Neurosci. 2025 Jan;48(1):1-2. Epub 2024 Nov 21 PubMed.

PAPER Sehlin D, Roshanbin S, Zachrisson O, Ingelsson M, Syvänen S

A brain-penetrant bispecific antibody lowers oligomeric alpha-synuclein and activates microglia in a mouse model of alpha-synuclein pathology.

Neurotherapeutics. 2025 Mar;22(2):e00510. Epub 2024 Dec 14 PubMed.

APP K724M

MUTATIONS APP 25891762 GRCh38/hg38 A T 27264074 GRCh37/hg19 A T Exon 17 Coding Increased Aβ42/Aβ40 ratio and Aβ42 levels in cultured cells. Unknown, but in one carrier, MRI revealed mild global brain atrophy and enlargement of the ventricles. K724M Alzheimer'

Frank Longo, Stephen Massa on Is It Time to Approve Drugs Based on Amyloid Removal?

COMMENT The Aisen et al. Perspective article argues that robust reduction of amyloid PET signal achieved by Aβ antibody-based therapies should serve as a surrogate biomarker of clinical response for approval of such treatments. The article provides a convincing s

Russell Swerdlow on Is It Time to Approve Drugs Based on Amyloid Removal?

COMMENT It is interesting that the datasets, studies, and arguments presented in this perspective paper bring others to different conclusions, and with an equal degree of conviction. rswerdlow 0

Jae-Hong Lee on Is It Time to Approve Drugs Based on Amyloid Removal?

COMMENT A surrogate marker for clinical outcomes in Alzheimer’s therapeutics has long been regarded as the Holy Grail in the field. It could definitely make new drug development much easier and faster. I agree with the authors of this position paper that, based o

Go to another page:

360
361
362
363
364
... 367

Current Filters

Date Range : Past 90 Days x

Remove all filters

SEARCH RESULTS

Purinergic-associated immune responses in neurodegenerative diseases.

Microglial upregulation of CD109 expression in spinal cord of amyotrophic lateral sclerosis mouse model and its role in modulating inflammation and TGFβ/SMAD pathway.

Protocol for handling and using SOD1 mice for amyotrophic lateral sclerosis pre-clinical studies.

Associations between adverse pregnancy outcomes and cognitive impairment and dementia: a systematic review and meta-analysis.

Strategies of positron emission tomography (PET) tracer development for imaging of tau and α-synuclein in neurodegenerative disorders.

Advanced AI techniques for classifying Alzheimer's disease and mild cognitive impairment.

Effects of Probiotics on Neurodegenerative Disease-Related Symptoms and Systemic Inflammation: A Systematic Review.